Treating Urge Incontinence in Older Women: A Cost-Effective Investment in Quality-Adjusted Life-Years (QALY)

about

Treating Urge Incontinence in Older Women: A Cost-Effective Investment in Quality-Adjusted Life-Years (QALY)

Item

http://www.wikidata.org/entity/Q59104199

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2015

@uk

name

Treating Urge Incontinence in ...... ity-Adjusted Life-Years (QALY)

@en

Treating Urge Incontinence in ...... in Quality-Adjusted Life-Years

@nl

type

Item

label

Treating Urge Incontinence in ...... ity-Adjusted Life-Years (QALY)

@en

Treating Urge Incontinence in ...... in Quality-Adjusted Life-Years

@nl

prefLabel

Treating Urge Incontinence in ...... ity-Adjusted Life-Years (QALY)

@en

Treating Urge Incontinence in ...... in Quality-Adjusted Life-Years

@nl

P1476

Treating Urge Incontinence in ...... ity-Adjusted Life-Years (QALY)

@en

P2093

Ali Bonakdar Tehrani

http://www.w3.org/2001/XMLSchema#string

Holly Langmuir

http://www.w3.org/2001/XMLSchema#string

Kathryn L. Burgio

http://www.w3.org/2001/XMLSchema#string

Patricia S. Goode

http://www.w3.org/2001/XMLSchema#string

Victoria L. Phillips

http://www.w3.org/2001/XMLSchema#string

P2860

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.

Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence

Prevalence and burden of overactive bladder in the United States.

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

Fesoterodine for the treatment of overactive bladder.

A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT).

Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2015/703425

http://www.w3.org/2001/XMLSchema#string

P478

2015

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime